Pharmacogenomics and individualized medicine: Translating science into practice

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 4, 2012, Pages 467-475

  Crews, K R ^a   Hicks, J K ^a   Pui, C H ^a   Relling, M V ^a   Evans, W E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; B RAF KINASE INHIBITOR; CIMETIDINE; CODEINE; CRIZOTINIB; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIGOXIN; DNA; METHOTREXATE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VEMURAFINIB; VKORC1 PROTEIN; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COLITIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TRANSPORT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GENOTYPE; HUMAN; KNOWLEDGE; LUNG ADENOCARCINOMA; MYOPATHY; NONHUMAN; PATIENT CARE PLANNING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866593873     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.120     Document Type: Article

References (73)

1. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283-289 (1998).
2. Cheok, M.H., Pottier, N., Kager, L. & Evans, W.E. Pharmacogenetics in acute lymphoblastic leukemia. Semin. Hematol. 46, 39-51 (2009).
3. Hopkins, M.M. et al. Putting pharmacogenetics into practice. Nat. Biotechnol. 24, 403-410 (2006).
4. Eichler, E.E. et al. completing the map of human genetic variation. Nature 447, 161-165 (2007).
5. Scherer, S.W. et al. challenges and standards in integrating surveys of structural variation. Nat. Genet. 39, S7-15 (2007).
6. Carlson, C.S., Eberle, M.A., Rieder, M.J., Smith, J.D., Kruglyak, L. & Nickerson, D.A. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat. Genet. 33, 518-521 (2003).
7. Hinds, D.A. et al. Whole-genome patterns of common DNA variation in three human populations. Science 307, 1072-1079 (2005).
8. Sachidanandam, R. et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
9. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics: SLcO1B1 variation and methotrexate disposition. Genome Res. 22, 1-8 (2012).
10. Gabriel, S.B. et al. the structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
11. Roses, A.D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
12. Cheng, Q., Yang, W., Raimondi, S.C., Pui, C.H., Relling, M.V. & Evans, W.E. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat. Genet. 37, 878-882 (2005).
13. Relling, M.V., Pui, C.H., cheng, C. & Evans, W.E. thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843-844 (2006).
14. Schwab, M. et al. Azathioprine therapy and adverse drug reactions in patients with infammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12, 429-436 (2002).
15. Yates, C.R. et al. Molecular diagnosis of thiopurine S-methyltransferase defciency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997).
16. Lennard, L., Lilleyman, J.S., Van Loon, J. & Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336, 225-229 (1990).
17. Lötsch, J., Rohrbacher, M., Schmidt, H., Doehring, A., Brockmöller, J. & Geisslinger, G. can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain 144, 119-124 (2009).
18. Kirchheiner, J. et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to cYP2D6 duplication. Pharmacogenomics J. 7, 257-265 (2007).
19. Rieder, M.J. et al. Efect of VKORc1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
20. Hofmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
21. Link, E. et al. SLcO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
22. Treviño, L.R. et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical efects. J. Clin. Oncol. 27, 5972-5978 (2009).
23. Ni, W. et al. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLcO1B1/OAtP1B1 in favopiridol disposition. PLoS ONE 5, e13792 (2010).
24. Zhu, M. & Zhao, S. candidate gene identifcation approach: progress and challenges. Int. J. Biol. Sci. 3, 420-427 (2007).
25. International HapMap consortium. the International HapMap Project. Nature 426, 789-796 (2003).
26. International HapMap consortium. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
27. Genomes Project consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
28. di Iulio, J. & Rotger, M. Pharmacogenomics: what is next? Front. Pharmacol. 2, 86 (2011).
29. Daly, A.K. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11, 241-246 (2010).
30. Wang, L., McLeod, H.L. & Weinshilboum, R.M. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
31. Shuldiner, A.R. et al. Association of cytochrome P450 2c19 genotype with the antiplatelet efect and clinical efcacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
32. Cooper, G.M. et al. A genome-wide scan for common genetic variants with a large infuence on warfarin maintenance dose. Blood 112, 1022-1027 (2008).
33. Yang, J.J. et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301, 393-403 (2009).
34. Sarasquete, M.E. et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 cYP2c8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112, 2709-2712 (2008).
35. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
36. Downing, J.R. et al. the pediatric cancer genome project. Nat. Genet. 44, 619-622 (2012).
37. Suhre, K. et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54-60 (2011).
38. Chen, R. et al. Personal omics profling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).
39. Ashley, E.A. et al. clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
40. Hayden, E.c. Sequencing set to alter clinical landscape. Nature 482, 288 (2012).
41. Mardis, E.R. the $1,000 genome, the $100,000 analysis? Genome Med. 2, 84 (2010).
42. Scott, S.A. et al. clinical Pharmacogenetics Implementation consortium guidelines for cytochrome P450-2c19 (cYP2c19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011).
43. Crews, K.R. et al. clinical Pharmacogenetics Implementation consortium (cPIc) guidelines for codeine therapy in the context of cytochrome P450 2D6 (cYP2D6) genotype. Clin. Pharmacol. Ther. 91, 321-326 (2012).
44. Johnson, J.A. et al. clinical Pharmacogenetics Implementation consortium Guidelines for cYP2c9 and VKORc1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
45. Dudley, J.T., Pouliot, Y., chen, R., Morgan, A.A. & Butte, A.J. translational bioinformatics in the cloud: an afordable alternative. Genome Med. 2, 51 (2010).
46. Genomes Project data available on Amazon cloud http://www.nih. gov/news/health/mar2012/nhgri-29.htm (2012).
47. Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011).
48. Dudley, J.t. et al. computational repositioning of the anticonvulsant topiramate for infammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
49. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450-458 (2012).
50. Shields, A.E. & Lerman, C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther. 83, 635-639 (2008).
51. Mccullough, K.B. et al. Assessment of the pharmacogenomics educational needs of pharmacists. Am. J. Pharm. Educ. 75, 51 (2011).
52. Relling, M.V. & Klein, t.E. cPIc: clinical Pharmacogenetics Implementation consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
53. Wong, W.B., carlson, J.J., Thariani, R. & Veenstra, D.L. cost efectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28, 1001-1013 (2010).
54. van den Akker-van Marle, M.E. et al. cost-efectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7, 783-792 (2006).
55. Hughes, A.R. et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confrmation to clinical utility. Pharmacogenomics J. 8, 365-374 (2008).
56. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Efectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).
57. Altman, R.B. Pharmacogenomics: "noninferiority" is sufcient for initial implementation. Clin. Pharmacol. Ther. 89, 348-350 (2011).
58. Robarge, J.D., Li, L., Desta, Z., Nguyen, A. & Flockhart, D.A. the star-allele nomenclature: retooling for translational genomics. Clin. Pharmacol. Ther. 82, 244-248 (2007).
59. Swen, J.J. et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673 (2011).
60. Relling, M.V. et al. clinical Pharmacogenetics Implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011).
61. Martin, M.A., Klein, t.E., Dong, B.J., Pirmohamed, M., Haas, D.W. & Kroetz, D.L. clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91, 734-738 (2012).
62. Wilke, R.A. et al. the clinical Pharmacogenomics Implementation consortium: cPIc Guideline for SLcO1B1 and Simvastatin-Induced Myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012).
63. Crews, K.R. et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am. J. Health. Syst. Pharm. 68, 143-150 (2011).
64. Roberts, J.D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379, 1705-1711 (2012).
65. McLeod, H.L. & Isaacs, K.L. Preemptive pharmacogenetic testing: insufcient data equal unsatisfactory guidance. Ann. Intern. Med. 154, 842-844 (2011).
66. Hamburg, M.A. & collins, F.S. the path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
67. Stocco, G. et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 85, 164-172 (2009).
68. Fernandez, C.A. et al. concordance of DMEt Plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92, 360-365 (2012).
69. Hicks, J.K. et al. Automated incorporation of pharmacogenetic consults into an electronic medical record. Clin. Pharmacol. Ther. (in press).
70. Mega, J.L. et al. Reduced-function cYP2c19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PcI: a meta-analysis. JAMA 304, 1821-1830 (2010).
71. Sof, F., Giusti, B., Marcucci, R., Gori, A.M., Abbate, R. & Gensini, G.F. cytochrome P450 2c19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 11, 199-206 (2011).
72. Amado, R.G. et al. Wild-type KRAS is required for panitumumab efcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
73. Evans, W.E. & McLeod, H.L. Pharmacogenomics\drug disposition, drug targets, and side efects. N. Engl. J. Med. 348, 538-549 (2003).